

On Behalf of:
Noven Pharmaceuticals, Inc.

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

**NOVEN PHARMACEUTICALS, INC.,
Petitioner**

v.

**NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
Patent Owners**

***Inter Partes* Review No.: 2014-00550
U.S. Patent No. 6,335,031**

**Declaration of Christopher J. Coulson Regarding
Exhibits 1044 and 1045**

I, Christopher J. Coulson, declare as follows:

1. I am an attorney at Kenyon and Kenyon LLP, counsel for Petitioner Noven Pharmaceuticals, Inc. (“Petitioner”) in the above-captioned *inter partes* review. My attorney registration number is 61,771. I respectfully submit this declaration in support of Petitioner’s Exhibit 1044 and 1045.

2. Exhibit 1044 is a true and correct copy of search results I caused to be obtained by entry the search term “rivastigmine-d6 tartrate” into the quick search window on the Toronto Research Chemicals Inc. website (available at <https://www.trc-canada.com/index.php>) followed by selection of “Details/Order” for rac Rivastigmine-d6 Tartrate Salt on March 23, 2015.

3. Exhibit 1045 is a true and correct copy of an article that I caused to be downloaded on March 24, 2015 from The Times of Israel website (available at www.timesofisrael.com), entitled “Alzheimer drug pioneer to get Israel Prize”.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct. I understand that willful false statements are punishable by fine or imprisonment or both. See 18 U.S.C. § 1001.

Dated: March 31 2015

/s/ Christopher J. Coulson
Christopher J. Coulson